Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis

Gianluigi Mancardi, Maria Pia Sormani, Paolo A. Muraro, Giacomo Boffa, Riccardo Saccardi

Research output: Contribution to journalReview article

Abstract

In the majority of relapsing multiple sclerosis patients, the disease can be quite easily controlled by already available, approved therapies. There are, however, some aggressive cases who continue to have clinical and magnetic resonance imaging (MRI) activity in spite of the treatment. These are the cases who may now receive benefit from intense immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT). In this review, we describe the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure. A description of the ideal patient who can take advantage of aHSCT is outlined and, finally, the ongoing studies which are near to completion or are close to starting are briefly reported.

Original languageEnglish
Pages (from-to)245-255
Number of pages11
JournalMultiple Sclerosis Journal
Volume24
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Hematopoietic Stem Cell Transplantation
Immunosuppression
Multiple Sclerosis
Therapeutics
Magnetic Resonance Imaging
Transplants
Safety
Mortality

Keywords

  • bone marrow transplantation
  • Haematopoietic stem cell transplantation
  • intense immunosuppression
  • multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. / Mancardi, Gianluigi; Sormani, Maria Pia; Muraro, Paolo A.; Boffa, Giacomo; Saccardi, Riccardo.

In: Multiple Sclerosis Journal, Vol. 24, No. 3, 01.03.2018, p. 245-255.

Research output: Contribution to journalReview article

@article{02e99f0aa7e44fd58470d395c272ad5d,
title = "Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis",
abstract = "In the majority of relapsing multiple sclerosis patients, the disease can be quite easily controlled by already available, approved therapies. There are, however, some aggressive cases who continue to have clinical and magnetic resonance imaging (MRI) activity in spite of the treatment. These are the cases who may now receive benefit from intense immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT). In this review, we describe the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure. A description of the ideal patient who can take advantage of aHSCT is outlined and, finally, the ongoing studies which are near to completion or are close to starting are briefly reported.",
keywords = "bone marrow transplantation, Haematopoietic stem cell transplantation, intense immunosuppression, multiple sclerosis",
author = "Gianluigi Mancardi and Sormani, {Maria Pia} and Muraro, {Paolo A.} and Giacomo Boffa and Riccardo Saccardi",
year = "2018",
month = "3",
day = "1",
doi = "10.1177/1352458517742532",
language = "English",
volume = "24",
pages = "245--255",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis

AU - Mancardi, Gianluigi

AU - Sormani, Maria Pia

AU - Muraro, Paolo A.

AU - Boffa, Giacomo

AU - Saccardi, Riccardo

PY - 2018/3/1

Y1 - 2018/3/1

N2 - In the majority of relapsing multiple sclerosis patients, the disease can be quite easily controlled by already available, approved therapies. There are, however, some aggressive cases who continue to have clinical and magnetic resonance imaging (MRI) activity in spite of the treatment. These are the cases who may now receive benefit from intense immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT). In this review, we describe the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure. A description of the ideal patient who can take advantage of aHSCT is outlined and, finally, the ongoing studies which are near to completion or are close to starting are briefly reported.

AB - In the majority of relapsing multiple sclerosis patients, the disease can be quite easily controlled by already available, approved therapies. There are, however, some aggressive cases who continue to have clinical and magnetic resonance imaging (MRI) activity in spite of the treatment. These are the cases who may now receive benefit from intense immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT). In this review, we describe the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure. A description of the ideal patient who can take advantage of aHSCT is outlined and, finally, the ongoing studies which are near to completion or are close to starting are briefly reported.

KW - bone marrow transplantation

KW - Haematopoietic stem cell transplantation

KW - intense immunosuppression

KW - multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85042877198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042877198&partnerID=8YFLogxK

U2 - 10.1177/1352458517742532

DO - 10.1177/1352458517742532

M3 - Review article

AN - SCOPUS:85042877198

VL - 24

SP - 245

EP - 255

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 3

ER -